Involvement of NLRP3 inflammasome in rituximab‐induced interstitial lung disease: a case report

H. Kong,Y. Wang,X. Zeng,Q. Zhu,W. Xie,S. Dai
DOI: https://doi.org/10.1111/jcpt.12198
2014-12-01
Journal of Clinical Pharmacy and Therapeutics
Abstract:Rituximab is a chimeric anti‐CD20 IgG1 monoclonal antibody for the treatment of various forms of lymphoma and haematological autoimmune diseases. Interstitial lung disease is a rare but lethal pulmonary toxicity of rituximab. Nod‐like receptor pyrin domain‐containing protein 3 (NLRP3) inflammasome is a molecular platform activated upon signs of cellular ‘danger’ to trigger the maturation of pro‐inflammatory cytokines. We report the first case of rituximab‐induced interstitial lung disease (R‐ILD) with NLRP3 inflammasome activation in the lung.
What problem does this paper attempt to address?